Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write

Game da kamfaninmuBayanin Maganin CAR-T

Maganin CAR-T, wanda aka yi wa lakabi da Chimeric Antigen Receptor T-Cell Immunotherapy, wata hanya ce ta zamani ta maganin kwayoyin halitta wadda ta ƙunshi gyara ƙwayoyin T na majiyyaci don kai hari da kuma lalata ƙwayoyin cutar kansa. Ba kamar magungunan gargajiya ba, maganin CAR-T an tsara shi ne ga kowane majiyyaci kuma yana buƙatar tattara ƙwayoyin T daga jinin majiyyaci kafin a sake haɗa su cikin jiki bayan injiniyan kwayoyin halitta.
BAYANIN CIWON JINI NA CAR-T (1)snmn
Bincika Siffofin

Alamomin CAR-T

● Cutar sankarar lymphoblastic mai tsanani ta B-cell

● Ciwon myeloma da yawa

● Ciwon sankarar lymphocytic na yau da kullun

● Ciwon sankarar lymphoid wanda ba Hodgkin ba

● Yaɗuwar babban ƙwayar cutar sankarar B-cell

● SLE (Tsarin Lupus Erythematosus)

Kyakkyawan aikin asibiti na CAR-T

Alamomi ga CD19+20CAR-T: Marasa lafiya da cutar lymphoma ba ta Hodgkin ba ta B-cell

Kudin CR na wata ɗaya

Kudin PR na wata ɗaya

Kudin wata ɗaya KO

CRS≥3

CRES≥3

71.95%(59/82)

25.6(21/82)

97.55(80/82)

12.19%(10/82)

0

Alamomi ga CD19+22CAR-T: Maganin cutar sankarar jini ta B-lymphocytic da ta sake dawowa da kuma wadda ba ta da tabbas a cikin CD19

Kudin CR na wata ɗaya

Kudin PR na wata ɗaya

Kudin wata ɗaya KO

CRS≥3

CRES≥3

92.1%(35/38)

Kashi 7.9%(3/38)

100%(38/38)

Kashi 15.79%(6/38)

0

Alamomi ga BCMACAR-T: Maganin sake dawowa da kuma rashin ƙarfin myeloma mai yawa

Kudin CR na wata ɗaya

Kudin PR na wata ɗaya

Kudin wata ɗaya KO

CRS≥3

CRES≥3

72.41%(21/29)

27.59%(8/29)

100% (29/29)

Kashi 6.9%(2/29)

0

BAYANIN CIWON JINI NA CAR-T (2)6u3

Me Yasa Zabi Mu?

Amfaninmu

Jiyya ta Musamman: Muna keɓance maganin CAR-T ga kowane majiyyaci, muna tabbatar da cewa an yi shi da kyau kuma yana da tasiri.

Zaɓuɓɓukan Manufofi Mabanbanta: Kayayyakinmu na CAR-T suna ba da zaɓuɓɓuka iri-iri na manufa, gami da CD7, CD19, CD20, CD22, da BCMA, suna ba da fa'idar zaɓuɓɓukan magani na musamman ga marasa lafiya.

Fasaha Mai Kyau: Maganinmu na CAR-T yana amfani da sabbin ci gaba a fannin injiniyan kwayoyin halitta da kuma maganin rigakafi.

Ingantaccen farashi mai kyau: Idan aka kwatanta da sauran kayayyaki, muna bayar da daidaito mafi kyau tsakanin tabbatar da inganci da farashi mai kyau.

Ƙwarewar Asibiti: Tare da goyon bayan ƙungiyar ƙwararrun likitoci da masu bincike, muna ba da kulawa mai inganci da tallafi a duk lokacin aikin jiyya.

Cikakken Tsarin Kulawa: Muna bayar da cikakken kulawa, tun daga tantance marasa lafiya zuwa bayar da magani da kuma bin diddigin marasa lafiya, don tabbatar da samun sakamako mai kyau.